logo
Plus   Neg
Share
Email

Marston's To Sell 137 Pubs To Admiral Taverns For £44.9 Mln - Quick Facts

British brewer and pub operator Marston's Plc (MARS.L) announced Monday that it has reached agreement for the disposal of 137 pubs to Admiral Taverns for 44.9 million pounds.

The company said the sale is in line with its plans to reduce debt in part through the disposal of certain non-core assets. The disposing assets are smaller wet-led leased, tenanted and franchised pubs. The deal is expected to complete before the end of November.

The pubs being disposed recorded EBITDA of 4.8 million pounds and operating profit of 3.7 million pounds for the year 2019. The pubs have a book value of 62.6 million pounds.

Marston's expects the disposal to result in average profit per pub in the retained estate increasing by around 7 percent and return on capital improving by 0.2% post the transaction.

Ralph Findlay, Chief Executive Officer, said, "We remain focused on our stated objective of reducing our net debt by £200 million by 2023 or earlier, and thereafter operating a high quality business generating consistent net cashflow, after dividends, of at least £50 million per annum."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
Follow RTT